Ulysses Management’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
Other funds holding MRNA
TP
Ulysses Management's MRNA Position: Q3 2026 in Review
Ulysses Management opened a new position in Moderna (MRNA) in Q3 2026: 2,000 shares worth $385K. The stake represents 0.05% of the portfolio and ranks #39 among its holdings. This is a return to the name: Ulysses Management previously reported a position in MRNA as recently as Q2 2023.
Ulysses Management first reported a position in MRNA in Q3 2022 and has held it in 4 quarters since. The position peaked at $1.08M in Q4 2022. 1,044 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.
- Ulysses Management held 2,000 shares of Moderna worth $385K as of Q3 2026.
- Moderna was a new Ulysses Management position in Q3 2026.
- Moderna made up 0.05% of Ulysses Management's portfolio in Q3 2026, its #39 holding.
- Ulysses Management first reported a position in Moderna in Q3 2022 and has held it in 4 quarters since.
- Ulysses Management's Moderna position peaked at $1.08M in Q4 2022.
- 1,044 funds tracked by Wall St. Rank held Moderna as of Q3 2026.
Based on Ulysses Management's 13F filing for Q3 2026, filed 16 Nov 2026.